R & D

Six-and-a-Half-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Continue to Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma

 This material is intended to notify the press release issued on May19 (local time) by Bristol Myers Squibb, our license partner for Opdivo.
 Please click for the original press release.